Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
TGTX - TG Therapeutics Inc
-1.90(-3.58%)9:00:00 PM 1/14/2021
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Stock news

    High Flying TG Therapeutics Needs a Period of Consolidation

    For his final "Executive Decision" segment, Jim Cramer checked in with Michael Weiss, executive chairman and CEO of TG Therapeutics , the biotech that just presented at the annual JP Morgan Healthcare Conference. A flat OBV line suggests that buyers and sellers are in balance.

    TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

    Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ETNEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference, being held virtually. The presentation is scheduled to take place on Tuesday, January 12, 2021 at 2:00 PM ET. A live webcast of this presentation will be available on the Events page, ...

    3 Soaring MedTech Stocks That Might Lose Ground in 2021

    Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

    Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?

    Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

    Is TGTX A Good Stock To Buy According To Hedge Funds?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

    TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

    NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 per share. Gross proceeds to the Company from the offering are expected to be approximately $275,000,000 before deducting underwriting discounts and commissions and estimate...

    TG Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it has commenced an underwritten public offering of $200,000,000 of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offer...